Opendata, web and dolomites

CRISS SIGNED

CRISPR Gene Correction for Severe Combined Immunodeficiency Caused by Mutations in Recombination-activating gene 1 and 2 (RAG1 and RAG2)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CRISS project word cloud

Explore the words cloud of the CRISS project. It provides you a very rough idea of what is the project "CRISS" about.

curative    editing    immunodeficiencies    interspaced    scids    hematopoietic    caused    corrective    clinically    manner    translate    clinical    contrast    containing    careful    stem    cellular    shown    limitations    mutations    causing    vectors    crispr    palindromic    trials    ada    homologous    cells    progenitor    genetic    mutation    hr    basic    wave    patients    rag1    beneficial    correction    functional    risks    clustered    therapy    born    precisely    clear    unable    rag2    transformation    efficacy    transgene    therapeutically    complete    disorders    fundamental    life    modifying    viral    transplantation    expressed    10    successfully    recombination    uncontrolled    bone    disease    diseases    hspcs    therapies    safety    methodical    patient    immune    transgenes    rag    correct    marrow    frequencies    fashion    active    cas9    protein    genome    threatening    stimulate    combined    science    genes    lineage    precise    developmental    severe    single    gene    scid    gt    allogeneic   

Project "CRISS" data sheet

The following table provides information about the project.

Coordinator
BAR ILAN UNIVERSITY 

Organization address
address: BAR ILAN UNIVERSITY CAMPUS
city: RAMAT GAN
postcode: 52900
website: www.biu.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 1˙372˙839 €
 EC max contribution 1˙372˙839 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2022-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BAR ILAN UNIVERSITY IL (RAMAT GAN) coordinator 1˙372˙839.00

Map

 Project objective

The severe combined immunodeficiencies (SCIDs) are a set of life threatening genetic diseases in which patients are born with mutations in single genes and are unable to develop functional immune systems. While allogeneic bone marrow transplantation can be curative for these diseases, there remain significant limitations to this approach. Gene therapy using viral vectors containing a corrective transgene is being developed for some of these disorders, most successfully for ADA-SCID. However, for other SCID disorders, such as those caused by genetic mutations in RAG1 and RAG2, the transgene needs to be expressed in a precise, developmental and lineage specific manner to achieve functional gene correction and to avoid the risks of cellular transformation. In contrast to using viral vectors to deliver transgenes in an uncontrolled fashion, we are working towards using genome editing by homologous recombination (HR) to correct the disease causing mutation by precisely modifying the genome. We have shown that by using clustered, regularly interspaced, short palindromic repeats (CRISPR) and the CRISPR-associated protein 9 (Cas9) system we can stimulate genome editing by HR at frequencies that should be therapeutically beneficial (>10%) in hematopoietic stem and progenitor cells (HSPCs). The overall focus of the proposal is to translate our basic science studies to use in RAG-SCID patient-derived HSPCs in methodical, careful and pre-clinically relevant fashion. The fundamental approach is to develop a highly active functional genome editing system using CRISPR-Cas9 for RAG-SCIDs and complete pre-clinical efficacy and safety studies to show the approach has a clear path towards future clinical trials. Our goal with this proposal is to develop the next wave of curative therapies for SCIDs and other hematopoietic disorders using genome editing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CRISS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CRISS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ENTRAPMENT (2019)

Septins: from bacterial entrapment to cellular immunity

Read More  

EASY-IPS (2019)

a rapid and efficient method for generation of iPSC

Read More  

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More